What diseases are Lynparib/Olaparib mainly used to treat? Detailed explanation of indications

Olaparib/Olaparib Trade name "Lipzo" is the world's first PARP (poly ADP ribose polymerase) inhibitor approved for marketing. Its clinical value is mainly reflected in the targeted treatment of tumor patients with defects in DNA damage repair pathways. The drug has been approved by multiple national drug regulatory agencies for the treatment of a variety of tumor types, including ovarian cancer, breast cancer, prostate cancer and pancreatic cancer, and has significantly improved the progression-free survival of advanced patients.

In the field of ovarian cancer, olaparib is widely used for maintenance treatment of patients with platinum-sensitive recurrent ovarian cancer, fallopian tube cancer or primary peritoneal cancer, especially for individuals with germline or somaticBRCA mutations. It can not only consolidate the curative effect after chemotherapy and delay disease recurrence, but is also used in first-line maintenance treatment combined with bevacizumab, especially in patients with HRD-positive patients. In the treatment of breast cancer, olaparib is suitable for patients with HER2-negative locally advanced or metastatic breast cancer carrying BRCA1 or BRCA2 germline mutations, and is also valuable in patients whose disease has progressed after neoadjuvant or adjuvant treatment, effectively prolonging patient survival and reducing the need for chemotherapy.

The indications of olaparib in prostate cancer have also been gradually established. It is mainly used to treat patients with metastatic castration-resistant prostate cancer (mCRPC) withHRR gene mutations (including BRCA1/2, ATM, etc.). It has shown good efficacy in precision treatment especially after failure of multiple lines of treatment. In addition, olaparib has also been approved for the treatment of patients with advanced pancreatic cancer with BRCA mutations. Its mechanism still relies on fatal defects in the DNA repair pathway, allowing the drug to accurately induce tumor cell apoptosis with less impact on normal cells.

It needs to be emphasized that the use of olaparib needs to be based on a clear genetic mutation background, especiallyThe detection results of BRCA mutations, so it is often used in clinical practice in conjunction with companion diagnostic technology to achieve "individualized treatment" in the true sense.

Reference materials:https://www.lynparza.com/